Analytical Data
-
Gene name
ADA
- Application
-
Alternative Names
ADA;ADA1;Adenosine deaminase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P00813
-
Expression Region
1-363aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MAQTPAFDKP KVELHVHLDG SIKPETILYY GRRRGIALPA NTAEGLLNVI GMDKPLTLPD FLAKFDYYMP AIAGCREAIK RIAYEFVEMK AKEGVVYVEV RYSPHLLANS KVEPIPWNQA EGDLTPDEVV ALVGQGLQEG ERDFGVKARS ILCCMRHQPN WSPKVVELCK KYQQQTVVAI DLAGDETIPG SSLLPGHVQA YQEAVKSGIH RTVHAGEVGS AEVVKEAVDI LKTERLGHGY HTLEDQALYN RLRQENMHFE ICPWSSYLTG AWKPDTEHAV IRLKNDQANY SLNTDDPLIF KSTLDTDYQM TKRDMGFTEE EFKRLNINAA KSSFLPEDEK RELLDLLYKA YGMPPSASAG QNL
-
Molecular Weight
43 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Adenosine deaminase (ADA) is a crucial enzyme that catalyzes the deamination of adenosine to inosine, playing a significant role in purine metabolism and maintaining immune homeostasis. Deficiencies in ADA activity can lead to severe combined immunodeficiency (SCID), a life-threatening condition characterized by the absence of functional T and B lymphocytes. As a result, ADA deficiency has garnered attention in medical research and therapeutic development. The study of ADA and its recombinant proteins has advanced our understanding of enzyme function, stability, and potential therapeutic applications. Recombinant ADA proteins are being investigated for enzyme replacement therapy (ERT) to restore enzyme function in affected individuals. Furthermore, understanding the structural and functional properties of ADA proteins through recombinant techniques allows for the development of novel therapeutic strategies, including gene therapy approaches. Research into ADA's role in immune regulation and its implications in various diseases, such as cancer and autoimmune disorders, highlights the enzyme's significance beyond SCID, encouraging further exploration of ADA-modulating therapies. This research background underscores the importance of ADA in both basic and clinical sciences, as well as the potential for innovative treatment options for patients with ADA-related disorders.











